metoprolol has been researched along with Idiopathic Parkinson Disease in 4 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To verify the previously reported association between long-term use of β2-adrenoreceptor (β2AR) agonist and antagonist with reduced and increased risk of Parkinson disease (PD), respectively." | 1.51 | Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. ( Blaabjerg, M; Christensen, K; Deuschl, G; Höglinger, GU; Hopfner, F; Kuhlenbäumer, G; Pottegård, A; Rösler, TW; Wod, M, 2019) |
| "Metoprolol (MP) was given intravenously to reduce blood pressure during surgery." | 1.35 | Noradrenergic modulation of subthalamic nucleus activity in human: metoprolol reduces spiking activity in microelectrode recordings during deep brain stimulation surgery for Parkinson's disease. ( Abdel Rahman, A; Castro-Prado, F; Coenen, VA; Gielen, FL; Honey, CR, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hopfner, F | 1 |
| Wod, M | 1 |
| Höglinger, GU | 1 |
| Blaabjerg, M | 1 |
| Rösler, TW | 1 |
| Kuhlenbäumer, G | 1 |
| Christensen, K | 1 |
| Deuschl, G | 1 |
| Pottegård, A | 1 |
| Coenen, VA | 1 |
| Gielen, FL | 1 |
| Castro-Prado, F | 1 |
| Abdel Rahman, A | 1 |
| Honey, CR | 1 |
| de Milliano, PA | 1 |
| van Eck-Smit, BL | 1 |
| de Groot, AC | 1 |
| Lie, KI | 1 |
| Allman, KC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-09-23 | Recruiting | ||
| The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease[NCT03775096] | Phase 2 | 15 participants (Anticipated) | Interventional | 2019-04-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for metoprolol and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adrenergic beta-Antag | 2019 |
Noradrenergic modulation of subthalamic nucleus activity in human: metoprolol reduces spiking activity in microelectrode recordings during deep brain stimulation surgery for Parkinson's disease.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Deep Brain Stimulation; Electroencephalo | 2008 |
Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Heart; Humans; Hyp | 2000 |
Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Heart; Humans; Hyp | 2000 |
Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Heart; Humans; Hyp | 2000 |
Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Heart; Humans; Hyp | 2000 |
Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Heart; Humans; Hypotension, Orthostatic; Iodine Radioisotopes; Metoprolol; My | 2001 |